Affimed N.V. (AFMD)
| Market Cap | 531.90M |
| Revenue (ttm) | 34.59M |
| Net Income (ttm) | -50.45M |
| Shares Out | 119.80M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 990,234 |
| Open | 4.36 |
| Previous Close | 4.41 |
| Day's Range | 4.20 - 4.45 |
| 52-Week Range | 4.20 - 11.74 |
| Beta | 2.50 |
| Analysts | Strong Buy |
| Price Target | 12.67 (+185.3%) |
| Earnings Date | Nov 10, 2021 |
About AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical s...
Analyst Forecast
According to 7 analysts, the average rating for Affimed stock is "Strong Buy." The 12-month stock price forecast is 12.67, which is an increase of 185.25% from the latest price.
News
Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provide...
HEIDELBERG, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference
HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology An...
HEIDELBERG, Germany, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq
Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-d...
HEIDELBERG, Germany, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer will h...
Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche's...
HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announ...
3 Best Biopharma Stocks to Buy During This Industrywide Fire Sale
Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now.
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
Affimed NV (NASDAQ:AFMD) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13. Eighte...
Why Affimed Stock Is On Fire Today
The biotech's early-stage trial results are turning heads on Wall Street today.
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Kille...
HEIDELBERG, Germany, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Why Affirmed Stock Was Up More Than 12% Wednesday
Positive trial results regarding the company's pipeline are buoying the stock's price.
Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstr...
HEIDELBERG, Germany, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed N.V. (AFMD) Reports Q3 Loss, Lags Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -30.77% and -13.34%, respectively, for the quarter ended September 2021.
Recap: Affimed Q3 Earnings
Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Wednesday, November 10, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
HEIDELBERG, Germany, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed to Present at Upcoming Investor Conferences
HEIDELBERG, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate C...
HEIDELBERG, Germany and SANTA ANA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) and NKGen Biotech, both clinical stage biotech companies focused on harnessing the power of the b...
Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia
HEIDELBERG, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and C...
HEIDELBERG, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Should You Buy?
Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021
HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
2 Biotech Stocks Set to Go Supernova Soon
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual ...
HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
New Strong Sell Stocks for September 29th
AFMD, FSLR, MU, BCE, and USNA have been added to the Zacks Rank #5 (Strong Sell) List on September 29, 2021.